Last reviewed · How we verify
Fusidic Acid 1%
Fusidic acid inhibits bacterial protein synthesis by binding to elongation factor G and preventing peptide chain elongation.
Fusidic acid inhibits bacterial protein synthesis by binding to elongation factor G and preventing peptide chain elongation. Used for Bacterial skin and soft tissue infections, Staphylococcus aureus infections (topical).
At a glance
| Generic name | Fusidic Acid 1% |
|---|---|
| Sponsor | Baxis Pharmaceuticals, Inc. |
| Drug class | Steroid antibiotic |
| Target | Bacterial elongation factor G (EF-G) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Fusidic acid is a steroid antibiotic that targets bacterial elongation factor G (EF-G), a critical component of the bacterial ribosome. By binding to EF-G and blocking its function, it prevents the translocation of peptides during protein synthesis, effectively halting bacterial growth. It is bacteriostatic and has particular activity against Gram-positive bacteria, including Staphylococcus aureus.
Approved indications
- Bacterial skin and soft tissue infections
- Staphylococcus aureus infections (topical)
Common side effects
- Local skin irritation
- Contact dermatitis
- Pruritus
Key clinical trials
- Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis (PHASE3)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2) (PHASE3)
- Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema (PHASE3)
- Efficacy of 100% Trichloroacetic Acid Vs. Cryotherapy in Xanthelasma Palpebrarum (NA)
- M. Hailey-Hailey: hSPCA1 Expression and Skin Structure Upon Laser Therapy (NA)
- The Healing Effects Of Honey and Hydrogel Products On The Diabetic Foot (EARLY_PHASE1)
- S. Aureus Decolonization in HPN Patients. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fusidic Acid 1% CI brief — competitive landscape report
- Fusidic Acid 1% updates RSS · CI watch RSS
- Baxis Pharmaceuticals, Inc. portfolio CI